Skip to main content
CBUS logo

Cibus, Inc. (CBUS) Stock Price & Analysis

Cibus, Inc. (CBUS) — MoonshotScore 18/100 (Weak band), calculated Oct 6, 2026. Price $1.57 (-6.55%), as of the Oct 6, 2026 trading session; market cap $120M.

Educational signal · not a buy or sell recommendation · How to read this

$1.57 −$0.11 (-6.55%) Market Cap $120M

Cibus, Inc. · CBUS · NASDAQ

Cibus, Inc. is an agricultural technology company specializing in the development and licensing of plant traits to seed companies. Their focus is on enhancing crop productivity and creating sustainable ingredients.

Price as of Oct 6, 2026

Key Statistics

18 of 100

MoonshotScore v2 · Cibus (CBUS)

Weak
Business Quality Poor (19)
Financial Safety Fragile (10)
Valuation Bubble (8)
Growth Durability Fading (30)
Momentum Slipping (31)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet, weak growth and an expensive valuation. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $994,000 (Q2 FY2026, quarter ended Jun 2026)
  • EPS beat 4 of 8
  • Altman Z -4.38 · Piotroski F 3

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CBUS (30 recorded, newest six shown)
RecordedScoreBand
16Weak
16Weak
16Weak
16Weak
16Weak
16Weak

The score moved from 16 in the stored Oct 5, 2026 snapshot to 18 in the current publication computed Oct 6, 2026 (+2); the largest pillar moves were Momentum -34. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.57
Change on the day-6.55%
52-week range$1.09 – $4.19
Market capitalisation$120M
Price / earnings (trailing)-2.17
Shares traded on the day163.4K

Price & events

Council Score · weighted blend of 2 available disciplines

Council score for Cibus (CBUS): Bearish Lean

31/100 · D

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Growth Durability Weak
Momentum Moderate
Business Quality Negative
Financial Safety Negative
Valuation Negative

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 6, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Negative
ROE Negative
Gross Margin Moderate

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Simons-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 6, 2026, except a card that shows its own read date.

Watch the CBUS film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is Cibus (CBUS), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cibus, Inc. (CBUS) is listed on NASDAQ. It employs 118 people and is led by Craig Wichner. In Q2 FY2026 it reported revenue of $994,000 and net income of -$22M. The market values it at $120M.

2 · Latest results

What do the latest results show for Cibus (CBUS)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $994,000. Against analyst estimates the company has EPS beat 4 of 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$994,000-$22M-$0.29 (diluted)
Q1 FY2026$2M-$21M-$0.33 (diluted)
Q4 FY2025$1M-$31M-$0.59 (diluted)
Q3 FY2025$615,000-$24M-$0.44 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Cibus (CBUS)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -4.38 · Piotroski F 3. Trailing ratios: ROA -11.2% · current ratio 2.37.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -4.38 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Cibus compare with its peers?

Short answer

Cibus's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
CorMedix Inc. (CRMD) Same industry, near in market value$7.28 Oct 6, 2026$571M94 5-pillar Oct 6, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$46.11 Oct 6, 2026$853M93 5-pillar Oct 6, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$10.70 Oct 5, 2026$633M91 5-pillar Oct 6, 2026
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.55 Oct 5, 2026$663M88 5-pillar Oct 6, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$17.08 Oct 6, 2026$90.6M82 5-pillar Oct 6, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$9.73 Oct 6, 2026$689M77 5-pillar Oct 6, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$4.38 Oct 6, 2026$179M76 5-pillar Oct 6, 2026
Niagen Bioscience Inc (NAGE) Same industry, near in market value$2.68 Oct 5, 2026$213M69 5-pillar Oct 6, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$10.97 Oct 6, 2026$628M69 5-pillar Oct 6, 2026
Q32 Bio Inc. (QTTB) Same industry, near in market value$8.11 Oct 6, 2026$241M68 5-pillar Oct 6, 2026
AN2 Therapeutics, Inc. (ANTX) Same industry, near in market value$5.61 Oct 5, 2026$202M67 5-pillar Oct 6, 2026
Alto Neuroscience, Inc. (ANRO) Same industry, near in market value$24.04 Oct 6, 2026$844M61 5-pillar Oct 6, 2026
Cibus (CBUS) — this page$1.57$120M18

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 8, 2026

Transactions
21
Identified insiders
13
Purchases
0
Sales
0
Other transactions
21

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

What has been published about Cibus (CBUS)?

Read these with our analysis →

Cibus Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the CBUS research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CBUS?

CBUS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Cibus, Inc. is an agricultural technology company specializing in the development and licensing of plant traits to seed companies.

Is CBUS a good stock to buy?

Stock Expert AI does not rate CBUS buy, sell or hold. Cibus, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CBUS stock price today?

The last price recorded on this page for Cibus, Inc. (CBUS) is $1.57, as of the Oct 6, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for CBUS?

Cibus, Inc. faces several risks inherent in the agricultural biotechnology sector. These include competition from larger agricultural companies with greater financial resources, regulatory hurdles and approval processes for its plant traits, and dependence on licensing agreements for revenue. Fluctuations in commodity prices can also impact the demand for Cibus's traits.

What are the key factors to evaluate for CBUS?

Cibus, Inc. (CBUS) holds a MoonshotScore in the low range. The company's primary focus is on productivity traits that enhance crop yields and reduce the use of chemicals and fertilizers. Not financial advice.

How frequently does CBUS data refresh on this page?

CBUS's price is the last quote we recorded, from the Oct 6, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CBUS's recent stock price performance?

Cibus, Inc. (CBUS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative plant trait technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CBUS overvalued or undervalued right now?

Cibus, Inc. (CBUS) is loss-making, so its trailing P/E is negative (-2.17x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of CBUS?

Fractional-share availability for Cibus, Inc. (CBUS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (18 figures)

The 18 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 10 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$1.57FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T20:05:17.871Z.
px.changeChange on the day-6.55%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$120MFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-06. FMP quote timestamp: 2026-10-06T20:00:01.000Z. Captured from FMP at 2026-10-06T20:05:16.908Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars−$0.11FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2026$994,000FMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.pePrice / earnings (trailing)-2.17FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day163.4KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q2 FY2026-$22MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2026FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
own.insidersInsider transactions via FMP21 transactions · 0 purchases, 0 sales, 21 other transactions · 13 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jun 8, 2026FMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

UNRECORDED — 6 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 4 of 8UNRECORDEDStored earnings-history observation — Captured 2026-09-16 · Expired observation
fin.scoresDistress and quality screensAltman Z -4.38 · Piotroski F 3UNRECORDEDStored financial-scores observation — Captured 2026-10-03 · Expired observation
px.range5252-week range$1.09 – $4.19UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.employeesEmployees118UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.ceoChief executiveCraig WichnerUNRECORDEDStored company-profile observation — Captured 2026-10-01
fin.ratiosReturn and yield ratios (trailing twelve months)ROA -11.2% · current ratio 2.37—UNRECORDEDStored key metrics — Date unknown

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v218 of 100 · Weak · pillars 19 / 10 / 8 / 30 / 31OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement16 (stored snapshot Oct 5, 2026) → 18 (current publication computed Oct 6, 2026) (+2)OURSStock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive.
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.